R&D Medicago

Our R&D pipeline: Exploring vaccines development

Medicago’s R&D teams are committed to explore vaccines development.

Today, Medicago dedicates its research and development of vaccines designed to help protect humans against viruses and future pandemics, and aims to extend the scope of its vaccines beyond viral diseases.

Our vaccine production platform is also capable of producing monoclonal antibodies. We are working on developing antibodies and therapeutic proteins that can be used to develop vaccines to help fight cancer, among other applications.

Projects under development

It is through the close collaboration of our scientists, technicians and engineers, we are developing innovative and unique vaccines and treatments to save lives. The following table provides an overview of projects currently under development.

Preclinical Phase 1 Phase 2 Phase 3 Registration

COVID-19

Pandemic Flu

Seasonal Flu, Adjuvanted

Next Generation Flu vaccine

COVID-19/FLU combo vaccine

Rotavirus

Norovirus